Meca-Lallana, José; Ayuso, Teresa; Martínez-Yelamos, Sergio; Duran, Carmen; Contreras-Martín, Yessica; Herrera-Navarro, Nicolas; Pérez-Sempere, Ángel; Álvarez-Cermeno, José-C; Millán-Pascual, Jorge; Meca-Lallana, Virginia; Romero-Sevilla, Raul; Ricart, Javier
(KARGER, 2020-05)
BACKGROUND: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). METHODS: Multicenter, observational ...